These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 10878512)

  • 1. [Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C].
    Olaso V; Córdoba J; Lòpez Viedma B; Siles MS; Molina JM; Prieto M; Baum I; Gobernado M; Berenguer J
    Rev Esp Quimioter; 1999 Sep; 12(3):220-8. PubMed ID: 10878512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
    Olaso V; Córdoba J; Molina JM; López B; Siles MS; Monte E; Calvo F; Bau I; Beltrán B; Martínez B; Gobernado M
    Rev Esp Quimioter; 2002 Dec; 15(4):366-73. PubMed ID: 12587043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
    Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C
    Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ROC curve analysis of factors predictive of non-response to interferon treatment in patients with chronic hepatitis C, genotype 1].
    Olaso V; Córdoba J; Siles MS; Molina JM; Esteban RJ; Garijo R; Mora J; Nicolás D; Gobernado M; Berenguer J; Segovia M
    Rev Esp Quimioter; 2000 Mar; 13(1):51-9. PubMed ID: 10855025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
    Diago M; Luján M; Valeros D; Tuset C; Marcaida G; García V; Cors R; Carbonell P
    Rev Esp Enferm Dig; 2001 Jun; 93(6):353-63. PubMed ID: 11482039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
    Mangia A; Minerva N; Annese M; Leandro G; Villani MR; Santoro R; Carretta V; Bacca D; Giangaspero A; Bisceglia M; Ventrella F; Dell'Erba G; Andriulli A
    Hepatology; 2001 Apr; 33(4):989-93. PubMed ID: 11283865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
    Colombatto P; Ciccorossi P; Maina AM; Civitano L; Oliveri F; Coco B; Romagnoli V; Bonino F; Brunetto MR
    Clin Pharmacol Ther; 2008 Aug; 84(2):212-5. PubMed ID: 18388885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ROC curve analysis of factors predictive of no response to interferon treatment in patients with chronic hepatitis C, genotype 1].
    Olaso V; Córdoba J; Siles MS; Molina JM; Esteban RJ; Garijo R; Mora J; Nicolás D; Gobernado M; Berenguer J; Segovia M
    Rev Esp Quimioter; 2000 Mar; 13(1):51-59. PubMed ID: 10878538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy.
    Radu C; Dejica D; Grigorescu M; Zaharie T; Neculoiu D
    Rom J Gastroenterol; 2003 Jun; 12(2):91-5. PubMed ID: 12853993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
    Mangi A; Villani MR; Minerva N; Leandro G; Bacca D; Cela M; Carretta V; Attino V; Ventrella F; Giangaspero A; Andriulli A
    J Hepatol; 2001 Mar; 34(3):441-6. PubMed ID: 11322207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative viremia test for early prediction of a biochemical response in patients with chronic hepatitis C treated with interferon.
    Nardiello S; Gaeta GB; Pizzella T; Stornaiuolo G; Ascione T; Galanti B; Giusti G
    J Chemother; 2001 Aug; 13(4):424-8. PubMed ID: 11589486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients.
    Kamar N; Lhomme S; Abravanel F; Cointault O; Esposito L; Cardeau-Desangles I; Del Bello A; Dörr G; Lavayssière L; Nogier MB; Guitard J; Ribes D; Goin AL; Broué P; Metsu D; Sauné K; Rostaing L; Izopet J
    Transplantation; 2015 Oct; 99(10):2124-31. PubMed ID: 26214817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.